Advances in Therapy

, Volume 30, Issue 1, pp 1–13

Treatment of Heavy Menstrual Bleeding with the Estradiol Valerate and Dienogest Oral Contraceptive Pill

Review

Abstract

The new estradiol valerate and dienogest oral contraceptive pill recently received U.S. Food and Drug Administration (FDA) approval to treat heavy menstrual bleeding in women without diagnosed uterine conditions.

This oral contraceptive formulation combines estradiol valerate, which is metabolically identical to natural estradiol, with the potent new progestin, dienogest. The four-phasic pill is effective for pregnancy prevention and leads to significantly decreased menstrual bleeding among women with heavy periods, and shorter and lighter periods among women with normal periods. Studies indicate that this formulation may be associated with decreased hepatic activation compared to contraceptive pills that contain ethinyl estradiol. However, whether these findings translate to a decreased risk of thrombotic events has not been determined, and the pill carries the same contraindications as all other combined hormonal contraceptives.

At least 10–15% of women suffer from heavy menstrual bleeding, defined as ≥80 mL of blood loss per cycle. In large clinical trials of women with heavy menstrual bleeding, the estradiol valerate and dienogest pill decreased blood loss volume by a median of 81%.

Women with heavy menstrual bleeding treated with this contraceptive pill can expect a significant reduction in bleeding after just one cycle of use. This therapy leads to a decrease in bleeding that may be greater than that achieved by different oral contraceptive pills or other medical therapies, including tranexamic acid and nonsteroidal anti-inflammatory drugs.

Keywords

Contraception Cycle control Estradiol valerate and dienogest oral contraceptive pill Heavy menstrual bleeding Menstrual bleeding Reproductive medicine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27:705–721.PubMedCrossRefGoogle Scholar
  2. 2.
    Hatcher RA, Trussell J, Nelson A, et al. Contraceptive technology. 20th edition. New York, NY: Ardent Media; 2011.Google Scholar
  3. 3.
    Prentice A. Fortnightly review. Medical management of menorrhagia. BMJ. 1999;319:1343–1345.PubMedCrossRefGoogle Scholar
  4. 4.
    National Collaborating Centre for Women’s and Children’s Health. Heavy menstrual bleeding. Commissioned by the National Institute for Health and Clinical Excellence. NHS NICE website. Available at: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf. Accessed May 12 2011.
  5. 5.
    Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913–920.PubMedCrossRefGoogle Scholar
  6. 6.
    Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009:CD000154.Google Scholar
  7. 7.
    Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol. 1971;110:713–720.PubMedGoogle Scholar
  8. 8.
    Mishell DR, Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol. 1982;142:809–816.PubMedGoogle Scholar
  9. 9.
    Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31:66–70.PubMedCrossRefGoogle Scholar
  10. 10.
    FDA approved drug products. U.S. Food and Drug Administration wesbite. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed Aug 30 2012.
  11. 11.
    Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol. 1988;158:1646–1652.PubMedGoogle Scholar
  12. 12.
    Goebelsmann U, Mashchak CA, Mishell DR, Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol. 1985;151:868–877.PubMedGoogle Scholar
  13. 13.
    Krishnan S, Kiley J. The lowest-dose, extendedcycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg. Int J Womens Health. 2010;2:235–239.PubMedGoogle Scholar
  14. 14.
    Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005:CD003989.Google Scholar
  15. 15.
    Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 1989;61:65–69.PubMedGoogle Scholar
  16. 16.
    Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106.PubMedCrossRefGoogle Scholar
  17. 17.
    Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol. 1998;50:458–464.PubMedCrossRefGoogle Scholar
  18. 18.
    Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 betaestradiol. Fertil Steril. 1993;60:616–619.PubMedGoogle Scholar
  19. 19.
    Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand. 1987;66:543–547.PubMedCrossRefGoogle Scholar
  20. 20.
    Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol. Br J Obstet Gynaecol. 1979;86:732–736.PubMedCrossRefGoogle Scholar
  21. 21.
    Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 1995;21:27–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996;54:333–338.PubMedCrossRefGoogle Scholar
  23. 23.
    Oettel M, Breitbarth H, Elger W, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care. 1999;4:2–13.CrossRefGoogle Scholar
  24. 24.
    Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data. 2004:1–36.Google Scholar
  25. 25.
    Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23. 2005:1–160.Google Scholar
  26. 26.
    Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41:241–250.PubMedCrossRefGoogle Scholar
  27. 27.
    Speroff L, Darney PD. A clinical guide for contraception. 5th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.Google Scholar
  28. 28.
    Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.PubMedCrossRefGoogle Scholar
  29. 29.
    Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss and iron deficiency. Acta Med Scand. 1966;180:639–6350.PubMedCrossRefGoogle Scholar
  30. 30.
    Zakherah MS, Sayed GH, El-Nashar SA, Shaaban MM. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest. 2011;71:281–284.PubMedCrossRefGoogle Scholar
  31. 31.
    Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009;31:340–347.PubMedGoogle Scholar
  32. 32.
    Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83:48–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181:1263–1269.PubMedCrossRefGoogle Scholar
  34. 34.
    Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th edition. Baltimore: Lippincott Williams & Wilkins; 2004.Google Scholar
  35. 35.
    Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;3:127–132.PubMedGoogle Scholar
  36. 36.
    Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78:218–225.PubMedCrossRefGoogle Scholar
  37. 37.
    Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149.PubMedCrossRefGoogle Scholar
  38. 38.
    Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266.PubMedCrossRefGoogle Scholar
  40. 40.
    Mabey R, Parke S, Mellinger U, Serrani M, Jensen J. Hormone withdrawal-associated symptoms: comparison of estradiol valerate/dienogest versus ethinylestradiol/norgestimate. Poster presentation at: American College of Obstetricians and Gynecologists Annual Clinical Meeting; May 5–9, 2012; San Diego, CA. Available at: http://www.postersessiononline.com/173580348_eu/congresos/60acog/aula/-Mo_8_60acog.pdf. Accessed Oct 17 2012.
  41. 41.
    Macias G, Merki-Feld G, Parke S, Mellinger U, Serrani M. Hormone withdrawal-associated symptoms in women taking combined oral contraceptives: comparison of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Poster presentation at: International Society of Gynecological Endocrinology Meeting; March 7–10, 2012; Firenze, Italy. Available at: http://www.isge2012.com/abstracts-posters/. Accessed Oct 17 2012.
  42. 42.
    Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117:33–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74:100–103.PubMedCrossRefGoogle Scholar
  44. 44.
    Have you missed your Natazia pill? Natazia® website. Available at: http://www.natazia.com/missed-your-pill.html. Accessed Aug 30 2012.
  45. 45.
    Palacios S, Wildt L, Parke S, Machlitt A, Romer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149:57–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Nelson A, Sampson-Landers C, Parke S, Jensen J. Efficacy of estradiol valerate/dienogest OC: results of 3 large studies in North America and Europe. Abstract plus poster presentation at: 57th Annual Clinical Meeting of the American College of Obstetricians & Gynecologists; May 2–6 2009, Chicago, IL.Google Scholar
  47. 47.
    Natazia® Prescribing Information. Bayer Healthcare website. Available at: http://berlex.bayerhealthcare.com/html/products/pi/natazia_pi.pdf. Accessed Aug 30 2012.
  48. 48.
    Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception. 2007;75:16–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80:436–444.PubMedCrossRefGoogle Scholar
  50. 50.
    Jensen J, Machlitt A, Mellinger U, Schaefers M, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117:777–787.PubMedCrossRefGoogle Scholar
  51. 51.
    Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reproduct. 2011;26:2698–2708.CrossRefGoogle Scholar
  52. 52.
    Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271–278.PubMedGoogle Scholar
  53. 53.
    Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012;86:96–101.PubMedCrossRefGoogle Scholar
  54. 54.
    Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11:159–170.PubMedCrossRefGoogle Scholar
  55. 55.
    Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–584.PubMedCrossRefGoogle Scholar
  56. 56.
    Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8:2841–2850.PubMedCrossRefGoogle Scholar
  57. 57.
    Nappi R, Davis S, Bitzer J, et al. Exploring the effect of oral contraceptives on female sexual function. Poster presentation at: Endocrine Society Meeting; June 23–26, 2012; Houston, TX. Available at: http://edrv.endojournals.org/cgi/content/meeting_abstract/32/03_MeetingAbstracts/P1-315?sid=5fbd5310-81c6-4888-8c6b-a5c64c36ae42. Accessed Oct 17 2012.
  58. 58.
    Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341–346.PubMedCrossRefGoogle Scholar
  59. 59.
    Strufaldi R, Pompei LM, Steiner ML, et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception. 2010;82:147–154.PubMedCrossRefGoogle Scholar
  60. 60.
    International Active Surveillance Study — Safety of Contraceptives: Role of Estrogen (INAS-SCORE). Clinical Trials website. Available at: http://clinicaltrials.gov/ct2/show/NCT01009684?term=inas&rank=1. Accessed Jun 21 2011.
  61. 61.
    Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroidrelated menorrhagia. Int J Gynaecol Obstet. 2011;112:126–130.PubMedCrossRefGoogle Scholar
  62. 62.
    Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:865–875.PubMedCrossRefGoogle Scholar
  63. 63.
    Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:625–632.PubMedCrossRefGoogle Scholar
  64. 64.
    Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112:1121–1125.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2012

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyUniversity of WashingtonSeattleUSA
  2. 2.Department of Obstetrics and GynecologyOregon Health and Science UniversityPortlandUSA

Personalised recommendations